Oral Session 1-7C Multiple Myeloma: Multicenter Clinical Trials

[OS1-7C-6] A phase 2 study of ixazomib plus lenalidomide and dexamethasone in Japanese RRMM patients

Makoto Sasaki¹, Tohru Izumi², Takuya Komeno³, Yasuhito Terui⁴, Takaaki Chou⁵, Takashi Ikeda⁶, Deborah Berg⁷, Shinichi Fukunaga⁸, Kenkichi Sugiura⁹, Shinsuke Iida¹⁰ (1.Division of Hematology, Juntendo University School of Medicine, 2.Department of Hematology, Tochigi Cancer Center, 3.Department of Hematology, National Hospital Organization Mito Medical Center, 4.Department of Hematology Oncology, Cancer Institute Hospital of JFCR, 5.Department of Internal Medicine, Niigata Cancer Center Hospital, 6.Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, 7.Takeda Clinical Research and Development, Takeda Pharmaceutical Company Limited, 8.Oncology Therapeutic Area Unit, Takeda Pharmaceutical Company Limited, 9.Biostatistics, Japan Development Center, Takeda Pharmaceutical Company Limited, 10.Department of Hematology and Oncology, Nagoya City University)